[Medication-related osteonecrosis of the jaw: a review and interpretation of international guidelines on oral health management].

Authors

J Zhang, S H Ge

Published in

Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology. Volume 61. Issue 8. Pages 1134-1142. Jul 30, 2026. Epub Jul 30, 2026.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ), a serious adverse effect associated with antiresorptive agents or certain antiangiogenic drugs, has become an important complication of concern to the fields of oral medicine, oncology, and bone metabolism disorders. Its prevention, early identification, and standardized management are of significant clinical importance. To guide clinical practice, several academic organizations have issued relevant guidelines or position papers. Although these guidelines are generally consistent in their overall principles, notable differences remain on certain key issues. This article takes the American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper as the central framework, and in conjunction with the Scottish Dental Clinical Effectiveness Programme (SDCEP) clinical guidance and other international consensus statements, reviews and analyzes the definition, risk factors, preventive measures, and treatment strategies for MRONJ. This approach aims to facilitate a more comprehensive understanding of the current evidence base and to provide clearer guidance for clinical practice.

PMID:
42532529
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.